Post removed.Why?

Post removed.Why?

Post removed.Why?

Post removed.Why?

Post removed.Why?

Post removed.Why?

Post removed.Why?

Post removed.Why?

Post removed.Why?

Post removed.Why?

Post removed.Why?

ORANG PAKISTAN LAGI PANDAI CARI WANG.

I WILL GO GENTING TO CELEBRATE THIS COMING CNY.

KUALA LUMPUR (Feb 2): RHB Research Institute and Kenanga Research have trimmed their target prices (TPs) for Supermax Corp Bhd due to a lack of visibility of its average selling prices (ASPs) and execution risk of its US venture.

Kenanga Research analyst Raymond Choo Ping Khoon, who kept his "outperform" call, said the research house had cut its TP to RM9.05 from RM7.80 previously based on 12 times calendar year 2022 estimated (CY22E) earnings per share (EPS) as the research house rolled over its valuation base from CY21 to CY22.

This was due to execution risk of the company's US venture to manufacture medical gloves and other personal protective equipment (PPE) with an initial capital outlay of RM405 million, as well as the lack of ASP visibility, he noted.

Supermax previously noted that while ASPs had not peaked in the first quarter of 2021 (1Q21) yet, demand is expected to moderate with the roll-out of Covid-19 vaccines.

As at the time of writing today, shares of Supermax had risen seven sen or 1.03% to RM6.87, valuing the group at RM18.69 billion. It had seen some 15.97 million shares traded.

Meanwhile, RHB Research Institute, which maintained its "buy" call on Supermax, lowered its TP to RM10.60 (from RM13.25), with a 56% upside and an about 7% yield.

“Our TP reflects 8.3 times FY22F P/E (price-earnings forecast for the financial year ending June 30, 2022; a 20% discount versus peers). This discount is justified due to Supermax’s lower market capitalisation. Our ‘buy’ call is premised on stronger earnings prospects for 3QFY21 (the third quarter ending March 31, 2021), an expected positive news flow from its venture to build a manufacturing plant in the US and its dual listing on the Singapore Exchange (SGX).

“We lower our TP to RM10.60. [Our] long-term ASP [assumptions] have been lowered to US$47 (RM190.04)/box (from US$48) as higher near-term ASPs should result in stronger competition in the long run. Beta has been increased to account for higher share price volatility,” said RHB analyst Alan Lim.

To recap, the glove maker’s net profit for the latest quarter, 2QFY21, climbed 34% quarter-on-quarter (q-o-q) to RM1.06 billion from RM789.52 million for the preceding 1QFY21, while quarterly revenue surged to RM2 billion compared with RM1.35 billion for the preceding quarter.

On a yearly basis, net profit jumped by a whopping 3,142% from RM30.17 million a year ago, while revenue also surged from RM385.5 million for the previous year.

However, despite cutting their TPs for Supermax, both research houses raised their earnings forecasts due to higher ASPs seen for the coming quarters.

Kenanga said it likes Supermax for its original brand manufacturing (OBM) model, which enables it to extract higher margins from distributor pieces compared to original equipment manufacturer (OEM) models at lower factory prices.

“[We] raise [our] FY21E/FY22E net profit by 27%/16% after hiking our ASP [assumptions] from US$65/1,000 pieces and US$45/1,000 pieces to US$70/1,000 pieces and US$50/1,000 pieces respectively,” said Choo.

RHB also increased its forecast for FY21 by 36% due to a higher ASP assumption.

“However, we maintain our FY22F-23F earnings as we keep [our] ASP assumptions unchanged. Note that our FY21-23F blended ASPs of US$89, US$57 and US$48 already assume an ASP decline in the future once Covid-19 ends,” said Lim.

In the short term, Lim said RHB expects earnings for Supermax to continue to rise for 3QFY21.

“Beyond that, Supermax is a beneficiary of stable glove growth demand of 8%-10% annually. Our ESG (environmental, social and governance) score for Supermax is 2.89,” added Lim.

KUALA LUMPUR (Feb 2): RHB Research Institute and Kenanga Research have trimmed their target prices (TPs) for Supermax Corp Bhd due to a lack of visibility of its average selling prices (ASPs) and execution risk of its US venture.

Kenanga Research analyst Raymond Choo Ping Khoon, who kept his "outperform" call, said the research house had cut its TP to RM9.05 from RM7.80 previously based on 12 times calendar year 2022 estimated (CY22E) earnings per share (EPS) as the research house rolled over its valuation base from CY21 to CY22.

This was due to execution risk of the company's US venture to manufacture medical gloves and other personal protective equipment (PPE) with an initial capital outlay of RM405 million, as well as the lack of ASP visibility, he noted.

Supermax previously noted that while ASPs had not peaked in the first quarter of 2021 (1Q21) yet, demand is expected to moderate with the roll-out of Covid-19 vaccines.

As at the time of writing today, shares of Supermax had risen seven sen or 1.03% to RM6.87, valuing the group at RM18.69 billion. It had seen some 15.97 million shares traded.

Meanwhile, RHB Research Institute, which maintained its "buy" call on Supermax, lowered its TP to RM10.60 (from RM13.25), with a 56% upside and an about 7% yield.

“Our TP reflects 8.3 times FY22F P/E (price-earnings forecast for the financial year ending June 30, 2022; a 20% discount versus peers). This discount is justified due to Supermax’s lower market capitalisation. Our ‘buy’ call is premised on stronger earnings prospects for 3QFY21 (the third quarter ending March 31, 2021), an expected positive news flow from its venture to build a manufacturing plant in the US and its dual listing on the Singapore Exchange (SGX).

“We lower our TP to RM10.60. [Our] long-term ASP [assumptions] have been lowered to US$47 (RM190.04)/box (from US$48) as higher near-term ASPs should result in stronger competition in the long run. Beta has been increased to account for higher share price volatility,” said RHB analyst Alan Lim.

To recap, the glove maker’s net profit for the latest quarter, 2QFY21, climbed 34% quarter-on-quarter (q-o-q) to RM1.06 billion from RM789.52 million for the preceding 1QFY21, while quarterly revenue surged to RM2 billion compared with RM1.35 billion for the preceding quarter.

On a yearly basis, net profit jumped by a whopping 3,142% from RM30.17 million a year ago, while revenue also surged from RM385.5 million for the previous year.

However, despite cutting their TPs for Supermax, both research houses raised their earnings forecasts due to higher ASPs seen for the coming quarters.

Kenanga said it likes Supermax for its original brand manufacturing (OBM) model, which enables it to extract higher margins from distributor pieces compared to original equipment manufacturer (OEM) models at lower factory prices.

“[We] raise [our] FY21E/FY22E net profit by 27%/16% after hiking our ASP [assumptions] from US$65/1,000 pieces and US$45/1,000 pieces to US$70/1,000 pieces and US$50/1,000 pieces respectively,” said Choo.

RHB also increased its forecast for FY21 by 36% due to a higher ASP assumption.

“However, we maintain our FY22F-23F earnings as we keep [our] ASP assumptions unchanged. Note that our FY21-23F blended ASPs of US$89, US$57 and US$48 already assume an ASP decline in the future once Covid-19 ends,” said Lim.

In the short term, Lim said RHB expects earnings for Supermax to continue to rise for 3QFY21.

“Beyond that, Supermax is a beneficiary of stable glove growth demand of 8%-10% annually. Our ESG (environmental, social and governance) score for Supermax is 2.89,” added Lim.

KUALA LUMPUR (Feb 2): RHB Research Institute and Kenanga Research have trimmed their target prices (TPs) for Supermax Corp Bhd due to a lack of visibility of its average selling prices (ASPs) and execution risk of its US venture.

Kenanga Research analyst Raymond Choo Ping Khoon, who kept his "outperform" call, said the research house had cut its TP to RM9.05 from RM7.80 previously based on 12 times calendar year 2022 estimated (CY22E) earnings per share (EPS) as the research house rolled over its valuation base from CY21 to CY22.

This was due to execution risk of the company's US venture to manufacture medical gloves and other personal protective equipment (PPE) with an initial capital outlay of RM405 million, as well as the lack of ASP visibility, he noted.

Supermax previously noted that while ASPs had not peaked in the first quarter of 2021 (1Q21) yet, demand is expected to moderate with the roll-out of Covid-19 vaccines.

As at the time of writing today, shares of Supermax had risen seven sen or 1.03% to RM6.87, valuing the group at RM18.69 billion. It had seen some 15.97 million shares traded.

Meanwhile, RHB Research Institute, which maintained its "buy" call on Supermax, lowered its TP to RM10.60 (from RM13.25), with a 56% upside and an about 7% yield.

“Our TP reflects 8.3 times FY22F P/E (price-earnings forecast for the financial year ending June 30, 2022; a 20% discount versus peers). This discount is justified due to Supermax’s lower market capitalisation. Our ‘buy’ call is premised on stronger earnings prospects for 3QFY21 (the third quarter ending March 31, 2021), an expected positive news flow from its venture to build a manufacturing plant in the US and its dual listing on the Singapore Exchange (SGX).

“We lower our TP to RM10.60. [Our] long-term ASP [assumptions] have been lowered to US$47 (RM190.04)/box (from US$48) as higher near-term ASPs should result in stronger competition in the long run. Beta has been increased to account for higher share price volatility,” said RHB analyst Alan Lim.

To recap, the glove maker’s net profit for the latest quarter, 2QFY21, climbed 34% quarter-on-quarter (q-o-q) to RM1.06 billion from RM789.52 million for the preceding 1QFY21, while quarterly revenue surged to RM2 billion compared with RM1.35 billion for the preceding quarter.

On a yearly basis, net profit jumped by a whopping 3,142% from RM30.17 million a year ago, while revenue also surged from RM385.5 million for the previous year.

However, despite cutting their TPs for Supermax, both research houses raised their earnings forecasts due to higher ASPs seen for the coming quarters.

Kenanga said it likes Supermax for its original brand manufacturing (OBM) model, which enables it to extract higher margins from distributor pieces compared to original equipment manufacturer (OEM) models at lower factory prices.

“[We] raise [our] FY21E/FY22E net profit by 27%/16% after hiking our ASP [assumptions] from US$65/1,000 pieces and US$45/1,000 pieces to US$70/1,000 pieces and US$50/1,000 pieces respectively,” said Choo.

RHB also increased its forecast for FY21 by 36% due to a higher ASP assumption.

“However, we maintain our FY22F-23F earnings as we keep [our] ASP assumptions unchanged. Note that our FY21-23F blended ASPs of US$89, US$57 and US$48 already assume an ASP decline in the future once Covid-19 ends,” said Lim.

In the short term, Lim said RHB expects earnings for Supermax to continue to rise for 3QFY21.

“Beyond that, Supermax is a beneficiary of stable glove growth demand of 8%-10% annually. Our ESG (environmental, social and governance) score for Supermax is 2.89,” added Lim.

Covid-19 cases in Malaysia cross 200k mark with 5,725 new cases reported while 24 new COVID-19 cases in Singapore, all imported.

Covid-19 cases in Malaysia cross 200k mark with 5,725 new cases reported while 24 new COVID-19 cases in Singapore, all imported.

Covid-19 cases in Malaysia cross 200k mark with 5,725 new cases reported while 24 new COVID-19 cases in Singapore, all imported.

Covid-19 cases in Malaysia cross 200k mark with 5,725 new cases reported while 24 new COVID-19 cases in Singapore, all imported.

Covid-19 cases in Malaysia cross 200k mark with 5,725 new cases reported while 24 new COVID-19 cases in Singapore, all imported.

Covid-19 cases in Malaysia cross 200k mark with 5,725 new cases reported while 24 new COVID-19 cases in Singapore, all imported.

Covid-19 cases in Malaysia cross 200k mark with 5,725 new cases reported while 24 new COVID-19 cases in Singapore, all imported.

Covid-19 cases in Malaysia cross 200k mark with 5,725 new cases reported while 24 new COVID-19 cases in Singapore, all imported.

BIASALAH

Singapore reports 10 new COVID-19 cases, all imported

Singapore reports 10 new COVID-19 cases, all imported

Singapore reports 10 new COVID-19 cases, all imported.

US MARKET BREAK NEW HIGH , I WILL SPEND 2 MIL BUY TOP GLOVES TOMORROW.

I WILL BUY MORE IF IT DROP FURTHER.

I WILL WITHDRAW MY FD 2MIL AND SWITCH TO TOP GLOVES FOR DIVIDEND TOMORROW.

I WILL NOT EAT MCDONALD AND COCA COLA .

I AM SO EXCITED TO GO SINGAPORE THIS FRIDAY TO GET VACCINATED. BYE BYE COVID 19.

I WILL INVEST 1 MIL ON AT ON MONDAY.

I WILL WEAR SUPERMAX GLOVES TO CELEBRATE CHRISTMAS TOMORROW.

I WILL INVEST 1 MIL ON SUPERMAX TOMORROW.

Post removed.Why?

I TAKE IT AS OPPORTUNITY FOR ME TO BUY CHEAP AND I THANK JP MORGAN FOR DOWNGRADING IT.

I WILL INVEST RM 500K TOMORROW.

UNCLE BAGI SIKIT TIPS UNTUK KITA, NAK CEPAT KAYA

BURSA MASTER KELUAR CARI MAKAN.

I WILL INVEST 300K TOMORROW DUE TO BONUS ISSUE.

I WILL INVEST 200 K TOMORROW. WELL SAID

MATILAH SAYA BELI 5000 RIBU LOT AT 0.285. RM 1,425,000

I WILL SELL ALL MY SHARES AND BUT AT ON MONDAY.

I WILL SELL ALL MY SHARES AND BUT AT ON MONDAY.

I WILL SELL ALL MY SHARES AND BUT AT ON MONDAY.

I WILL SELL ALL MY SHARES AND BUT AT ON MONDAY.

I WILL SELL ALL MY SHARES AND BUT AT ON MONDAY.

I WILL SELL ALL MY SHARES AND BUT AT ON MONDAY.